Eyepoint Pharmaceuticals Inc (EYPT) Stock: What Does the Chart Say Friday?

Eyepoint Pharmaceuticals Inc (EYPT) stock is up 4.06% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Eyepoint Pharmaceuticals Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on EYPT!

See Full EYPT Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With EYPT Stock Today?

Eyepoint Pharmaceuticals Inc (EYPT) stock is trading at $6.66 as of 1:03 PM on Friday, Nov 17, an increase of $0.48, or 7.77% from the previous closing price of $6.18. The stock has traded between $6.15 and $6.81 so far today. Volume today is 434,746 compared to average volume of 453,584. To screen for more stocks like Eyepoint Pharmaceuticals Inc click here.

More About Eyepoint Pharmaceuticals Inc

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome Technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Click Here to get the full Stock Report for Eyepoint Pharmaceuticals Inc stock.